|
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. |
Lenvatinib, everolimus, and the combination in patients with metastatic ren... |
Wednesday, October 21, 2015 |
The Lancet Oncology |
|
Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC |
Consensus on the management of intracranial germ-cell tumours |
Wednesday, September 16, 2015 |
The Lancet Oncology |
|
Rintoul RC, Treasure T, Macbeth F |
Multimodal treatment for malignant pleural mesothelioma |
Friday, November 6, 2015 |
The Lancet Oncology |
|
Treasure T, Rintoul RC, Macbeth F |
SABR in early operable lung cancer: time for evidence |
Wednesday, May 20, 2015 |
The Lancet Oncology |
|
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sr... |
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in p... |
Wednesday, October 28, 2020 |
The Lancet Oncology |
|
Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, et al. |
Hypofractionated radiotherapy versus conventionally fractionated radiothera... |
Tuesday, November 3, 2015 |
The Lancet Oncology |
|
Wong HH, Halford S |
Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? |
Monday, October 5, 2015 |
The Lancet Oncology |
|
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. |
Cediranib or placebo in combination with cisplatin and gemcitabine chemothe... |
Friday, July 17, 2015 |
The Lancet Oncology |
|
Tan CS, Gilligan D, Pacey S |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-c... |
Wednesday, September 16, 2015 |
The Lancet Oncology |
|
Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S |
Evolving treatment options for melanoma brain metastases |
Monday, October 5, 2015 |
The Lancet Oncology |
